Bradley Radoff and Jumana Capital filed a joint 13D on Genesco Inc., disclosing a 7.6% stake in the Nashville-based footwear and apparel retailer. The disclosure positions the activist pair to push for board seats or operational changes at a company whose shares closed at $28.14 on the filing date, down from a five-year high near $47 in early 2022. Genesco operates 1,425 retail locations under banners including Journeys, Schuh, and Johnston & Murphy, with trailing twelve-month revenue of $2.1 billion and an enterprise value near $380 million.

Radoff, who previously served on the board of Perry Ellis International before its $437 million takeout by SPARC Group in 2023, specializes in underperforming specialty retail. Jumana Capital, a New York-based value shop managing roughly $180 million, typically partners with named activists rather than leading campaigns. The joint structure suggests Radoff will handle board-level engagement while Jumana provides capital and credibility with institutional holders. Genesco's board has ten seats, none of which turn over at the next annual meeting scheduled for June 2025 under Delaware staggered-board rules. The company has no poison pill on file as of this disclosure.

Genesco's core problem is margin compression at Journeys, which generates 58% of consolidated revenue but saw comparable-store sales decline 6% in the most recent quarter. The teen footwear channel faces structural headwinds from direct-to-consumer brand shifts and mall traffic declines. Management has closed 87 underperforming doors over the past eighteen months but has not articulated a clear turnaround thesis beyond cost cuts. Meanwhile, Johnston & Murphy—the company's dress footwear and retail division—operates at mid-single-digit EBITDA margins despite owning its brand and real estate, a fact likely to draw activist scrutiny. Radoff's Perry Ellis playbook involved portfolio simplification and real estate monetization; Genesco owns 34 Johnston & Murphy stores outright and holds long-term leases on another 140, creating optionality.

Operators should watch for three catalysts over the next ninety days. First, whether Radoff files an amended 13D requesting board representation or proposing specific operational changes, typically within thirty days of initial disclosure. Second, whether institutional holders—BlackRock and Vanguard together own 22%—file updated 13F positions in mid-February, signaling whether they added on the activist news. Third, whether Genesco management announces accelerated closures or brand divestitures ahead of its March earnings call, preempting activist pressure. The company's next quarterly report is scheduled for March 13, 2025, with fiscal year-end on February 1.

Genesco has $62 million in net debt and generates roughly $45 million in annual free cash flow, giving management room to negotiate but limiting buyback firepower. The stock trades at 0.18x trailing sales and 5.2x forward EBITDA, below footwear peer medians of 0.35x and 7.1x respectively, implying the market prices in continued operational deterioration absent intervention.